Quantcast
Home > Quotes > AVDL
AVDL

Avadel Pharmaceuticals plc American Depositary Shares (AVDL) Quote & Summary Data

$2.19
*  
0.04
1.79%
Get AVDL Alerts
*Delayed - data as of Jul. 15, 2019  -  Find a broker to begin trading AVDL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AVDL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 2.45 / $ 2.18
Share Volume
158,403
50 Day Avg. Daily Volume
380,378
Previous Close
$ 2.23
52 Week High / Low
$ 7.27 / $ 1.03
Market Cap
81,808,569
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
158,403
50 Day Avg. Daily Volume:
380,378

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.59

Trading Range

The current last sale of $2.19 is 112.62% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.45 $ 7.27
 Low: $ 2.18 $ 1.03

Company Description (as filed with the SEC)

(Dollar amounts in thousands, except per-share amounts and as otherwise noted) General Overview Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel," the "Company," "we," "our," or "us") is a branded specialty pharmaceutical company. Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our "unapproved marketed drug" (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com..  ... More ...  



Risk Grade

Where does AVDL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.24
Open Date:
Jul. 15, 2019
Close Price:
$ 2.19
Close Date:
Jul. 15, 2019


Consensus Recommendation

Analyst Info